The Impact of Vitamin D Supplementation on the IFNγ-IP10 Axis in Women with Hashimoto's Thyroiditis Treated with Levothyroxine: A Double-blind Randomized Placebo-controlled Trial.

What Was Tested

Researchers studied Vitamin D, K2, Magnesium and Zinc in this randomized controlled trial publication.

ELISA method was used to determine serum levels of vitamin D, tumor necrosis factor-alpha (TNF-α), IFN-γ, and IP10.

Why It Was Studied

Hashimoto's thyroiditis (HT) results from chemoattraction of inflammatory cells toward the thyroid gland by inducing the production of interferon-gamma (IFNγ)-induced protein 10 (IP10) by T helper (Th) 1 cells.

Vitamin D may suppress the IFNγ-IP10 axis, but this new function of vitamin D has not yet been investigated in HT patients.

Who Took Part

The study group was 40 patients.

PubMed tags the participants as women only.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Vitamin D, K2, Magnesium and Zinc study, the assignments were hidden from both participants and investigators until the end.

Some patients received a placebo instead of Vitamin D, K2, Magnesium and Zinc, giving a reference point.

What Was Measured

The CD4+ T cells of 40 patients were isolated, and the mRNA expression levels of vitamin D receptor (VDR), peroxisome proliferator-activated receptors (PPAR)-α, and PPAR-γ genes were determined by real-time PCR.

PubMed files the paper under topics including Chemokine CXCL10, Cholecalciferol, Dietary Supplements, Hashimoto Disease, Interferon-gamma, Peroxisome Proliferator-Activated Receptors and RNA, Messenger.

The authors tagged it with the keywords CD4-positive T-lymphocytes, Th1 cells and Vitamin D.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 40 patients.

The publication is from 2022 (Iranian journal of allergy, asthma, and immunology), a journal based in Iran.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.